RBD4059 clinical trials
Also written RBD4059.
How each study uses RBD4059 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the RBD4059 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- RBD4059
- 3
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
Who runs them
Industry 3 · Other 0
Suzhou Ribo Life Science Co. Ltd. (2) · Ribocure Pharmaceuticals AB (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test RBD4059.
- Aug 2027Phase I Trial of RBD4059 in Chinese Healthy ParticipantsPhase 1 · Suzhou Ribo Life Science Co. Ltd.
Studies
Open first, then newest update. How each study uses RBD4059 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase I Trial of RBD4059 in Chinese Healthy ParticipantsNot yet recruitingPhase 1Suzhou Ribo Life Science Co. Ltd.NCT07930767Written as RBD4059
- A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy SubjectsCompletedPhase 1Suzhou Ribo Life Science Co. Ltd.NCT05653037Written as RBD4059
- A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery DiseaseCompletedPhase 2Ribocure Pharmaceuticals ABNCT06717074Written as RBD4059
What changed recently
From the registry's own updates since Oct 15, 2026.
Newly registered1
- Phase I Trial of RBD4059 in Chinese Healthy ParticipantsNov 12, 2026NCT07930767